Cost of developing new drugs may be far lower than industry claims, trial reveals
theguardian.com/global-develop…

Join this Thursday! Kim Witczak 💜 at Consilium! Sign up here: mailchi.mp/consilium-scie… PharmedOut Erick Turner @eturnermd1.bsky.social John A Hickman HealthSense Florian Naudet Kindly #deprescribe -- taper psychiatric drugs MedWithdrawal Prof. Peter C Gøtzsche Ali Zeck Pharmacovigilance and Drug Safety Drug Safety Research David Juurlink Kevin Knopf

Pharma marketing in 1919 in 🇫🇷: Cocaine hydrochloride, recommended « for speakers, singers and teachers ».

Here’s a periodic reminder that our 16 years of work on HealthNewsReview,org can still be found on the Internet Archive Wayback Machine: web.archive.org/web/2019033117…

Never before had the American Academy of Neurology advertised a drug in its annual Congress. The first #AANAM plenary started with a 5-minute video on how to deliver lecanemab to patients with #Alzheimers . As American Academy of Neurology I feel betrayed. The AAN sold some of its soul today.

Another example of FDA lowering the bar 4 approval. When a trial fails on the primary outcome, it's negative or (at best) 'supportive', but then you'd need another trial 2 B strongly positive. Here it looks like there WAS no 2nd trial since Chris said 'a [singular] large trial'.

Hard 2 fathom that this unethical practice isn't also illegal. Reminds me of Joseph Ross's paper on guest authorship 4 Vioxx m-script, but authorship shenanigans came 2 light only via litigation. Here authorship is being sold in way that's blatant & shameless. Jennifer E. Miller

'Pazdur says he would like to see more diverse views during the OPH session, not just individuals curated by the sponsor to present ‘a very positive picture’ of the drug.'

'Curated'...that's a good word to describe the process

10 doctors on FDA panel for Abbott heart device had financial ties to the company nbcnews.com/health/health-… via @nbcnews

Good to see another null trial published. Another step towards destigmatization and a more realistic and credible body of published literature

🕵🏽‍♀️Want to become an evidence detective?
🛟Want to avoid common pitfalls when reading clinical drug trials?

Watch our webinar recording ⤵️

#CriticalAppraisal pearls for clinicians:
ti.ubc.ca/evidence-detec…

Featuring @lessismoremed + Aaron M Tejani 😍😍

Report from ICER on MAPS' MDMA therapy. 'we have substantial concerns about validity of results...unblinded...very strong prior beliefs of those involved in the trials...therapists encouraged favorable reports by patients and discouraged negative reports' icer.org/wp-content/upl…

Read this report on MAPS (now Lykos) MDMA trials. I don’t know what bearing this will have on FDA.

1/2 Very important article, in the most well known mainstream US psychiatry rag.
'Lastly, and most importantly, we have an ethical duty to our patients to take an honest look at the evidence derived from our research when making decisions that will impact their mental health.'

Michael Dougherty Michael Dougherty heads the Psychology Dept University of Maryland, Baltimore.

He has been updating tenure and promotion criteria within his dept and beyond to focus more on rigorous research.

He's also developed a toolkit for others to use: osf.io/z9xsr/

In case you didn't see it yet: I'm hiring a postdoc to work on improving reproducibility in research. Application deadline March 20:
ki.varbi.com/en/what:job/jo…

Abysmal rates of reporting clinical trial results in academia & gov't (4-13%) compared to industry (67%)
transparimed.org/single-post/cl…

Hundreds of Nordic clinical trials remain unpublished
cochrane.org/news/hundreds-…